(Q26827936)

5

object named as

Catherine Alix-Panabières

0 references

François-Clément Bidard

1

object named as

François-Clément Bidard

0 references

author name string

Michail Ignatiadis

3

1 reference

Jeffrey B. Smerage

4

1 reference

Wolfgang Janni

6

1 reference

Carlo Messina

7

1 reference

Costanza Paoletti

8

1 reference

Volkmar Müller

9

1 reference

Daniel F. Hayes

10

1 reference

Martine Piccart

11

1 reference

Jean-Yves Pierga

12

1 reference

language of work or name

1 reference

June 2013

1 reference

Cancer and Metastasis Reviews

1 June 2013

5 references

13 March 2019

3 April 2019

17 June 2019

12 October 2019

14 September 2020

6 references

13 March 2019

3 April 2019

17 June 2019

12 October 2019

14 September 2020

32

1 reference

issue

1-2

1 reference

page(s)

179-88

1 reference

Creative Commons Attribution 2.0 Generic

copyright license

start time

6 November 2012

1 reference

April 2022 Public Data File from Crossref

copyright status

copyrighted

0 references

cites work

HER-2 gene amplification can be acquired as breast cancer progresses

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3655223

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3655223

Circulating tumor cells, disease progression, and survival in metastatic breast cancer

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3655223

Development of circulating tumor cell-endocrine therapy index in patients with hormone receptor-positive breast cancer.

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3655223

Assessment of circulating tumor cells and serum markers for progression-free survival prediction in metastatic breast cancer: a prospective observational study

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3655223

Four-year follow-up of trastuzumab plus adjuvant chemotherapy for operable human epidermal growth factor receptor 2-positive breast cancer: joint analysis of data from NCCTG N9831 and NSABP B-31.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3655223

Artificial neural network analysis of circulating tumor cells in metastatic breast cancer patients

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3655223

Prospective analysis of the impact of VEGF-A gene polymorphisms on the pharmacodynamics of bevacizumab-based therapy in metastatic breast cancer patients

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3655223

Detection and HER2 expression of circulating tumor cells: prospective monitoring in breast cancer patients treated in the neoadjuvant GeparQuattro trial

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3655223

Prognosis of women with metastatic breast cancer by HER2 status and trastuzumab treatment: an institutional-based review

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3655223

Determination of HER2 status using both serum HER2 levels and circulating tumor cells in patients with recurrent breast cancer whose primary tumor was HER2 negative or of unknown HER2 status

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3655223

Variation of circulating tumor cell levels during treatment of metastatic breast cancer: prognostic and therapeutic implications

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3655223

Study of the biologic effects of lapatinib, a reversible inhibitor of ErbB1 and ErbB2 tyrosine kinases, on tumor growth and survival pathways in patients with advanced malignancies

31 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3655223

Clinical value of circulating endothelial cells and circulating tumor cells in metastatic breast cancer patients treated first line with bevacizumab and chemotherapy.

31 May 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9398-0

Circulating tumor cell detection predicts early metastatic relapse after neoadjuvant chemotherapy in large operable and locally advanced breast cancer in a phase II randomized trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9398-0

Single circulating tumor cell detection and overall survival in nonmetastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9398-0

Trastuzumab clears HER2/neu-positive isolated tumor cells from bone marrow in primary breast cancer patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9398-0

Trastuzumab decreases the incidence of clinical relapses in patients with early breast cancer presenting chemotherapy-resistant CK-19mRNA-positive circulating tumor cells: results of a randomized phase II study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9398-0

HER2 status of circulating tumor cells in patients with metastatic breast cancer: a prospective, multicenter trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9398-0

Multi-center study evaluating circulating tumor cells as a surrogate for response to treatment and overall survival in metastatic breast cancer

21 January 2018

1 reference

https://pubmed.ncbi.nlm.nih.gov/23129208

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

HER2 status and benefit from adjuvant trastuzumab in breast cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/23129208

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Molecular detection of cytokeratin-19-positive cells in the peripheral blood of patients with operable breast cancer: evaluation of their prognostic significance

1 reference

https://pubmed.ncbi.nlm.nih.gov/23129208

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1007/S10555-012-9398-0

1 reference

Dimensions Publication ID

1053144083

0 references

1 reference

1 reference

PubMed publication ID

23129208

1 reference